Transfer pricing and tax deductions upheld on established principles, while employee contributions and warranty provisions returned for fresh examinat...
Captive transfer pricing relies on industrial consumer tariffs, while genuine quotations can benchmark effluent treatment transfers under the Other Me...
Specific tariff classification for ophthalmic instruments and extended limitation principles determine the treatment of duty demands, confiscation, an...
Integrated golf function determines classification, placing launch monitors and simulators under other golf equipment rather than measuring instrument...
Public servant status under anti-corruption law extends to recognised stock exchange leadership; constitutional and sanction challenges do not succeed...
Acquiescence, homebuyer protection and clean-slate resolution principles prevent landowners from disrupting an integrated project through late termina...
Page of 4792
Press 'Enter' after typing page number.
1001 to 1020 of 95833 Results
❮
❯
❯❯
0 / 200
Expand Note
Add to Folder
No Folders have been created
+
Are you sure you want to delete "My most important" ?
This notification amends the export policy condition for cough syrup under Chapter 30 of Schedule-II (Export Policy) of ITC (HS) 2022. The existing policy mandated testing and obtaining a Certificate of Analysis from specified laboratories for exporting cough syrup. The revised policy introduces exemptions from this testing requirement in certain situations: (i) If the cough syrup is exported to USA, UK, Canada, EU, Japan, Australia, Singapore, South Korea, and Switzerland, and the manufacturing plant/section is approved by the regulatory agencies of these countries, testing is not required. (ii) If the cough syrup is manufactured in a plant/section approved by the regulatory agencies of the above-mentioned countries for any product, it can be exported to any country without testing. The effect is to waive mandatory testing for cough syrup exports in line with required GMP standards when exported to or manufactured in facilities approved by specified countries' regulatory agencies.
This notification amends the export policy condition for cough syrup under Chapter 30 of Schedule-II (Export Policy) of ITC (HS) 2022. The existing policy mandated testing and obtaining a Certificate of Analysis from specified laboratories for exporting cough syrup. The revised policy introduces exemptions from this testing requirement in certain situations: (i) If the cough syrup is exported to USA, UK, Canada, EU, Japan, Australia, Singapore, South Korea, and Switzerland, and the manufacturing plant/section is approved by the regulatory agencies of these countries, testing is not required. (ii) If the cough syrup is manufactured in a plant/section approved by the regulatory agencies of the above-mentioned countries for any product, it can be exported to any country without testing. The effect is to waive mandatory testing for cough syrup exports in line with required GMP standards when exported to or manufactured in facilities approved by specified countries' regulatory agencies.
Note: It is a system-generated summary and is for quick reference only.